Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 1998

View Archived Issues

Response to hypertensive effects of Bay-k-8644 is enhanced in pregnancy

AVI BioPharma: Q3 1998 highlights

Chiron reports phase II results of novel Meningococcus C vaccine trial

SkyePharma and Novartis enter collaboration for new Foradil formulation

Ilex Oncology: Q3 and nine-month 1998 highlights

Novavax: Q3 1998 highlights

Fujisawa: fiscal year 1999 interim highlights

Genta initiates another phase I/IIa prostate cancer trial with G-3139

Mechanism of action of CI-958, a potential agent for prostate cancer in phase II trials

Dual 5-HT reuptake inhibitor/5-HT1A antagonist discussed at neuroscience meeting

Acadia reaches milestone in Allergan collaboration and first clinical candidate is selected

Lidak shareholders approve company name change to Avanir

Akorn announces U.S. market introduction for BioLon

Synthelabo describes new series of serotonergic antagonists

Lamivudine prodrugs targeting macrophages reported by European investigators

Immunex receives U.S. patent protection for TACE

Heterocyclic hypoglycemic agents from SB for diabetes and related disorders

Pyridazine and phthalazine derivatives from SmithKline Beecham for CNS, neurological disorders

Novel CRF1-specific ligands claimed by Neurogen

Substituted heteroaromatic 5-ht1f agonists in development at Lilly as antimigraine agents

Hoechst to demerge, focus on life sciences business

Abbott discontinues development of asthma therapeutic

First marketing approval granted for Vitrase in Mexico; U.S. phase III trials now under way

Synapton NDA is nonapprovable, FDA says

COX-2-specific inhibitor from Merck filed for approval with FDA

New agents for glioblastoma in preclinical testing at Wayne Hughes Institute

Tasmar sales suspended in Canada

New treatment for aldosterone-related disorders discovered by French research team